<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211206053290N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-04-22</date_registration>
      <primary_sponsor>Sanandaj University of Medical Sciences</primary_sponsor>
      <public_title>Therapeutic Efficacy of Pistacia atlantica essential oil in the treatment of Recurrent Aphthous Stomatitis referred to Kowsar hospitals of Sanandaj</public_title>
      <acronym></acronym>
      <scientific_title>Therapeutic Efficacy of Pistacia atlantica essential oil in the treatment of Recurrent Aphthous Stomatitis referred to Kowsar hospitals of Sanandaj in 2022</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-02-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/60592</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The sample will be assigned to 2 groups at random, so that patients with the condition will be assigned to a double block (A and B) by the researcher. Then a package containing 100 cards with one of the letters A and B (50 each) is considered to randomly select a card from the package and enter one of the groups according to the Latin letter. In this way, 50 people are assigned to each group. Sampling is done in parallel in 2 groups until the number of samples is completed, Blinding description: Blinding (double-blind) means that both the participants and the researchers or the outcome assessors will not be aware of the random assignment of the study subjects to one of the intervention or control groups, because the random assignment based on blocking to one of the groups It was done with special numbers and using sealed envelopes, and receiving the medicine and placebo, considering that they are the same in color, shape, taste and smell, they are not able to know about the allocation of study groups.</study_design>
      <phase>3</phase>
      <hc_freetext>Aphthous Stomatitis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The intervention group will be prescribed Teriadent ointment. How use it is that, The gel will be applied topically 3 times a day (with an approximate weight of 200 mg containing 3 mg of essential oil) on the lesion on the swab for 20 to 30 seconds.(Product of Zhiran Daneshpojohan company). Intervention 2: Control group: The control group will be prescribed Teriadent ointment. How use it is that, The gel will be applied topically 3 times a day (with an approximate weight of 200 mg containing 3 mg of essential oil) on the lesion on the swab for 20 to 30 seconds.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All patient information will be kept confidential by researchers. Data analysis and article publishing will also be done.

When:
From 2023 and 1 year before the publication of the results

To whom:
Researcher.

Conditions:
The data file will be available as an article publication

Where to obtain:
The main performer

How to obtain:
Formal request to the Vice Chancellor for Research and Technology of the University and the main executor

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Jamal Amjadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Pasdaran Ave</address>
        <city>Sanandaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1344666177</zip>
        <telephone>+98 87 3366 4654</telephone>
        <email>amjadijamal@yahoo.com</email>
        <affiliation>Sanandaj University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr.Jamal Amjadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Pasdaran Ave</address>
        <city>Sanandaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6617713446</zip>
        <telephone>0098733611231</telephone>
        <email>amjadijamal@yahoo.com</email>
        <affiliation>Sanandaj University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>No more than 2 days have passed since the onset of aphthous ulcers.
Have not used any other treatment for their wounds before going to the clinic.
Patients have completed the consent to participate in the trial.
Be in the age group over 18 years.
People with a clear history of plague should be reported at least twice a year.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>People are allergic to the compounds and drugs used in the trial.
Failure to follow the recommended instructions during the study
Patients with systemic diseases such as diabetes, asthma, renal and hepatic insufficiency, epilepsy, blood and glandular disorders as well as pregnant women
Patients taking antibiotics or anti-inflammatory drugs for other reasons.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>ICD-10 K12</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Aphthous stomatitis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The intervention group will be prescribed Teriadent ointment. How use it is that, The gel will be applied topically 3 times a day (with an approximate weight of 200 mg containing 3 mg of essential oil) on the lesion on the swab for 20 to 30 seconds.(Product of Zhiran Daneshpojohan company)</i_keyword>
      <i_keyword>Control group: The control group will be prescribed Teriadent ointment. How use it is that, The gel will be applied topically 3 times a day (with an approximate weight of 200 mg containing 3 mg of essential oil) on the lesion on the swab for 20 to 30 seconds.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Follow-up time to observe changes and improvement in aphthous lesions will be on days zero (during the first visit to the doctor), 1 (first examination) on days 7 and 10 (follow-up) after starting treatment, which will be done by referring patients to the clinic. The studied variables include the number of wounds, the size of the wounds, the amount of pain and burning, and the amount of erythema and exudate. This information will be recorded each time the patient is examined in a special form along with the patient's demographic information. Timepoint: Follow-up time to observe changes and improvement in aphthous lesions will be on days zero (during the first visit to the doctor), 1 (first examination) on days 7 and 10 (follow-up) after starting treatment, which will be done by referring patients to the clinic. Method of measurement: Wound size will be measured by a special Williams dental probe. Also, the number of mouth ulcers will be counted at the beginning of the day and during the study period. The scale of burning and pain consists of a line of 10 cm, which means zero, no pain and 10 maximum pain. The patient determines the points that indicate pain, then from zero to that point will be measured and a numerical scale from one to 100 mm will be recorded.Pain intensity in patients will be measured based on the Visual Analog Scale (VAS). This pain scale represents a 10 cm line printed with markers at each end on a piece of paper. It is "painless" at one end and "worst pain" or "indescribable pain" at the other. The person places a cross × on the line to indicate the severity of their pain. A doctor then measures the line with a ruler to get a pain score.For children, pain scales using face images are commonly used. A child may express pain with pictures of eight different faces with different expressions. The child chooses a face that feels more in tune with their current level of pain.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Sanandaj University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-01-18</approval_date>
        <contact_name>Ethics Committee of Kurdistan University of Medical Sciences</contact_name>
        <contact_address>Pasdaran Ave, In front of Shadi Hotel Sanandaj Kurdistan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
